Neutrophil-to-lymphocyte ratio as a prognostic factor in patients with castration-resistant prostate cancer treated with docetaxel-based chemotherapy: a meta-analysis

Table 2 Subgroups for OS analysis

Subgroup	Studies, no	HR(95%CI)	P value	Heterogeneity
Subgroup	Studies, no	HR(95%CI)	P value	I²	P value
Overall	14	1.86 (1.55–2.23)	< 0.00001	46%	0.03
Sample size
<150	8	2.11 (1.64–2.72)	< 0.00001	37%	0.13
≥150	6	1.65 (1.25–2.16)	= 0.0003	55%	0.05
Publication year
2021–2022	3	2.14 (1.59–2.88)	< 0.00001	0%	0.52
2013–2020	11	1.80 (1.46–2.23)	< 0.00001	51%	0.03
Region
Asia	7	2.45 (1.91–3.13)	< 0.00001	0%	0.81
Non-Asia	7	1.57 (1.29–1.92)	< 0.0001	44%	0.10
Cutoff
≤ 3	10	1.87 (1.54–2.29)	< 0.00001	47%	0.05
>3	4	1.97 (1.15–3.39)	= 0.01	55%	0.09

ISSN: 1471-2490